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Abstract
Objective
Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx)
tests it is important to assess whether they provide good value for money. This review pro-
vides an update of the literature.
Methods
A literature search was performed in PubMed and papers published between August 2010
and September 2014, investigating the cost-effectiveness of PGx screening tests, were
included. Papers from 2000 until July 2010 were included via two previous systematic
reviews. Studies’ overall quality was assessed with the Quality of Health Economic Studies
(QHES) instrument.
Results
We found 38 studies, which combined with the previous 42 studies resulted in a total of 80
included studies. An average QHES score of 76 was found. Since 2010, more studies were
funded by pharmaceutical companies. Most recent studies performed cost-utility analysis,
univariate and probabilistic sensitivity analyses, and discussed limitations of their economic
evaluations. Most studies indicated favorable cost-effectiveness. Majority of evaluations did
not provide information regarding the intrinsic value of the PGx test. There were consider-
able differences in the costs for PGx testing. Reporting of the direction and magnitude of
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Conclusions
Application of PGx tests was mostly found to be a cost-effective or cost-saving strategy. We
found that only the minority of recent pharmacoeconomic evaluations assessed the intrinsic
value of the PGx tests. There was an increase in the number of studies and in the reporting
of quality associated characteristics. To improve future evaluations, scenario analysis
including a broad range of PGx tests costs and equal costs of comparator drugs to assess
the intrinsic value of the PGx tests, are recommended. In addition, robust clinical evidence
regarding PGx tests’ efficacy remains of utmost importance.
Introduction
Pharmacogenetics and pharmacogenomics investigate the influence of genetic and genomic
variations on drug response in individuals [1]. The term pharmacogenetics covers the study of
single genes, whereas pharmacogenomics is used to describe the study of several genes [1]. The
abbreviation PGx is used to cover both pharmacogenetics and pharmacogenomics. PGx tests
offer great opportunities for personalised medicine, by combining genetic information and cor-
responding phenotypes [2]. Ideally, by applying PGx, the most optimal, tailored pharmaco-
therapy can be determined, thereby increasing the treatment’s overall efficacy and decreasing
the incidence of adverse events [1]. In the field of oncology it has been shown that for certain
therapies the specific genetic variations in cancer cells can affect the drug efficacy and/or
adverse events [2]. Hence, patients may benefit from the PGx tests by utilising an alternative
therapy, or changing the drug dosage [3,4]. Therefore, PGx is nowadays often used as a syno-
nym for personalised medicine, although personalized medicine is a much broader concept
[2].
It is likely that an increasing amount of patient-specific genomic information will be avail-
able in the near future and this may result in an increased usage of PGx tests which needs eval-
uation of effects, but also cost effectiveness [5]. PGx has the potential to reduce the costs
associated with inappropriate, expensive drug treatments and/or serious adverse drug reac-
tions, in particular those that require hospitalisation [3]. Therefore, next to optimising health
outcomes, PGx tests might be cost-saving [1,5]. However, in order to obtain valid, accurate,
and relevant estimates of cost-effectiveness, reliable economic studies are required.
Economic evaluations of PGx tests entail some specific difficulties. Often there is no hard
clinical evidence regarding the effects of the PGx test on the clinical utility and it is unlikely
that such evidence will be available for the use of every genetic variant [6]. Furthermore, for
PGx tests, compliance and adherence of clinicians to the test results might have an effect on the
effectiveness of PGx tests which is hard to incorporate in a cost-effectiveness analysis [7]. Dif-
ferences in costs for the PGx test can be substantial between countries, or even laboratories,
and therefore it is advised to include different costs in scenario analysis [7]. In addition, the
sensitivity and specificity of a PGx test can vary due to different ethnicities studied, or genetic
variations analysed.
In the last decade, several reviews investigated economic evaluations of genetic tests [1,8–
14]. These reviews showed that the level of consistency and quality could be improved. Many
original studies lacked a thorough sensitivity analysis and moreover, in general a poor quality
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of methodology was noticed [9,11]. Inconsistencies mainly resulted from e.g. lack of clinical
evidence, different methodologies as well as statistics and modest heterogeneity among study
designs and patient populations [3,9]. However, these different methodologies have not been
in detail dealt with in previous systematic reviews. Recent developments have led to a bifurca-
tion in the nature of the economic evaluations of PGx testing in, on the one hand, studies
assessing the intrinsic value of a test and, on the other hand, studies assessing the value of the
test in combination with an active compound. For example in colorectal cancer, the economic
value of testing for KRAS as compared to no testing could be considered the “intrinsic value” of
the PGx test. KRAS testing before treatment with cetuximab, is found to be dominant (i.e. cost-
saving and better) as compared to no prior testing and therefore it is recommended before
administration of cetuximab [15]. By its uptake in clinical guidelines, a shift in the comparator
for future economic evaluations took place, as the combination of cetuximab and KRAS testing
became usual care. In future evaluations, the intrinsic value of the KRAS test itself will no lon-
ger be assessed, but rather the combination of a drug and its test as compared with a new treat-
ment option. Following this development, a distinction between the nature of economic
evaluations of PGx tests is important for a fair comparison of studies.
The objective of this study was to give recommendations for improvement and an update of
the literature about PGx tests, taking into account the difference between the intrinsic value of
tests themselves and tests embedded into economic evaluations as usual care or best current
care. Our new findings were placed in perspective with respect to findings from our previous
reviews [1,9]. As such, our study links together a period from 2000- September 2014 of PGx
testing and pharmacoeconomics.
Methods
A search in PubMed was performed using combinations of the following terms [PubMed
search: all fields] and their thesauri variants: [‘cost-effectiveness [including MeSH)’ OR ‘cost-
utility’ OR ‘cost-benefit’ OR ‘cost-minimization’OR ‘pharmacoeconomics [including MeSH]’]
AND [‘pharmaco-genetics’OR ‘pharmacogenomics [including MeSH]’ OR ‘genotyping’ OR
‘genetic screening’ OR ‘genetic testing [including MeSH]’ OR ‘genotyped’OR ‘polymorphism
screening’]. These search terms were in line with the terms that were used in previous reviews,
performed in 2008 and 2010 [1,9]. The search was last updated in October 2014 and studies
were included if they were: published between August 2010 and September 2014, peer
reviewed, performed on a genetic screening method of the human genome, evaluating eco-
nomic outcomes, written in English, and the genetic or genomic variations were shown to
influence the drug efficacy or drug safety. Articles were first screened on title. If the title was
not informative enough to form a decision with respect to these criteria, abstracts were
assessed. Additional articles were identified through reference tracking.
From the selected studies, the following data were extracted: (I) area of disease or patient
population, (II) gene(s) analysed by the pharmacogenetic test, (III) the costs of the pharmaco-
genetic test, (IV) pharmaceutical compound influenced by the genetic variation, (V) type of
economic analysis, (VI) type of sensitivity analysis, (VII) time horizon, (VIII) discounting, (IX)
perspective, (X) the outcome measurements, and (XI) the funding body. For interpretation of
the outcome measure (i.e. cost-effectiveness), the conclusions as reported by the authors were
used. Furthermore, an assessment of the papers ‘discussion on the study limitations’ was made.
In this assessment, all limitations mentioned by the authors were captured to look for common
and uncommon themes. As stated in the previous review, assessment of these points is
expected to provide good information for an adequate interpretation of the studies design,
reporting, robustness, methodologies used, and statistical analyses performed [9]. In addition
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to these points, which were assessed in our previous reviews, we added (XII) reporting of ana-
lytical validity of the PGx test, (XIII) the cost-effectiveness threshold, (XIV) the country which
was used for the perspective of the economic evaluation, and (XV) a weighted quality assess-
ment for the studies included by this update. To assess the quality, the Quality of Health Eco-
nomic Studies (QHES) instrument was used [16]. This instrument was used to improve
generalisability of the results with respect to other reviews performed in the same field [10,13].
According to the QHES checklist a score between 0 and 100 was generated. A score of 75
was considered as a high quality score [11]. Two reviewers assessed the quality of the included
studies, if results were different, consensus was reached through discussion.
Data from before 2008, and for the period 2008—July 2010 were retrieved from the two pre-
vious reviews by Vegter et al. (2008, 2010) [1,9].
Results
Included studies
Results of the search strategy are provided in a PRISMA flow chart (Fig 1) [17]. The PubMed
search yielded 4408 hits. Duplicates were removed and out of the remaining 733 articles, 160
were selected for full text assessment. Three articles were identified through reference tracking.
After inspection of full texts, 122 studies were excluded, resulting in 38 included studies
[15,18–54]. Main reasons for exclusion were the type of genetic tests studied (i.e. not related to
pharmacogenetics) and review papers. Subsequently, 42 studies published before July 2010
were added based on the two reviews by Vegter et al. [1,9,55–96], resulting in a final inclusion
of 80 studies. Fig 2A provides an overview of the total of 80 studies, published from 2000 until
September 2014, sorted by the type of pharmacoeconomic analysis performed. Most studies
were published in 2012 (16%), with a total of 13 publications.
Type of analysis: intrinsic value or combination with new drug
Cost utility analysis (CUA) was the technique mostly applied, namely in 54 studies (68%). Cost-
effectiveness analysis (CEA) was performed in 20 studies (25%), cost minimization analysis
(CMA) was used 5 times (6%). Note that for the sake of clarity we explicitly differentiate between
CUA (with results expressed in cost per QALY) and CEA (with other parameters for effective-
ness). Before 2008, CEA was the most frequently applied study type. Since 2008, CUA was per-
formed in most of the publications. Some studies directly assessed the intrinsic value of the PGx
test [15,18–22,24–28], while other studies applied scenarios in which equal costs and efficacy
were assumed for the drug related to the PGx tests and the alternative treatment [23,29]. Both
were considered cost-effectiveness estimates that provide an indication of the intrinsic value of
the PGx test (Table 1). However, we found that the majority of the newly included (i.e. since
2010) CEAs incorporated a PGx test strategy in combination with a drug and compared this
combination to another drug (Table 2). As such, the intrinsic value of the PGx test itself was not
assessed. For example, Handorf et al. compared therapy for non-small cell lung cancer with a
platinum combination to PGx selected treatment with erlotinib [44]. In this analysis, the cost-
effectiveness of the PGx test itself was not assessed, but the combination of the PGx test and erlo-
tinib. This makes the outcome mainly dependent on the price of erlotinib. The incremental cost-
effectiveness ratios (ICER) of base case scenarios are shown in Tables 1 and 2.
Costs of PGx tests
When comparing the costs of the PGx tests, considerable differences between the costs of the
tests were observed. This is not surprising, since technology of genetic testing is developing and
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costs are likely to be further reduced in the future. This was demonstrated by two studies of
which one was performed in 2012 [41) and one in 2013 [40]. The costs for this particular
screening test, US$72 and £20 respectively, were considerably lower compared to screening
costs in studies performed in 2009 and 2010, which ranged from US$175 until US$575, respec-
tively [63,78,96]. Another substantial difference was seen in the costs for the CYP2C9 and
VKORC1 tests, which ranged from £20 to US$575 [40,78].
Fig 1. PRISMA flow chart of the literature search.
doi:10.1371/journal.pone.0146262.g001
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Fig 2. Type of outcome analysis (A) and sensitivity analysis (B) of PGx studies from 2000- September 2014.
doi:10.1371/journal.pone.0146262.g002
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Table 1. Outcomes and funding sources of pharmaco-economic PGx studies on the intrinsic value of PGx test. Published between August 2010 and
September 2014. Note that numbers were rounded towards hundreds.
1st Author
(reference)
PGx test Analytical
validity
PGx test
reported
OutcomeMeasure Quantitative
outcome or
ICER (US$)
Cost
effectiveness
threshold
($/QALY)
Conclusion
based on
outcome
Funding Country QHES
score
Klang 2010 [18] 21 gene
assay
No QALY $10,800 No number Cost-effective Teva
Pharmaceutical
Industries Ltd.
Israel 83
Bacchi 2010 [19] 21- gene
assay
No Costs $800 saved per
patient
n.a. Cost-saving Unknown Brazil 34
Hall 2012 [20] 21 gene
assay
No QALY $8,900 £20,00–30,00
($31,200–
46,700)
Cost-effective,
though
substantial
uncertainty
Academic
resources
UK 90
Vanderlaan2011
[21]
21 gene
assay
No QALY $4,4009 saved
per patient per
year
n.a. Dominant Genomic Health,
Inc.
USA 31
Verhoef 2013
[22]
CYP2C9
and
VKORC1
No QALY €2,700 ($3200) €20,000
($24,200)
Cost-effective European grant Netherlands 87
Dong 2012 [23] HLA-B
*1502
Yes QALY $29,800* $50,000 Cost-effective for
Singaporean
Chinese and
Malays, but not
for Singaporean
Indians.
Academic
resources
Singapore 63
Tiamkao 2013
[24]
HLA-B
*1502
Yes Costs 98,600 baht
($3,000) saved
per 100 cases
n.a. Cost-effective None Thailand 48
Shiroiwa 2010
[15]
KRAS No QALY and LYG Dominant n.a. Dominant Roche
Diagnostics K.K.
Japan 90
Blank 2011 [25] KRAS
and
BRAF
Yes QALY KRAS and BRAF
saves €3,300
($2,500) per
patient
n.a. Cost saving Academic
resources
Switzerland 83
Behl 2012 [26] KRAS
and/or
BRAF
No LYS KRAS alone
saves $7,500 per
patient
n.a. Cost saving Academic
resources
USA 84
Additional BRAF
testing saves
$1,000 per
patient
Shiffman 2012
[27]
LPA No QALY $25,000 No number Could be cost-
effective
Berkeley
HeartLab, Inc.
USA 34
Donnan 2011
[28]
TPMT Yes Life months Cost no test CAN
$700 ($600) per
patient- Cost
genetic test CAN
$1,100 ($900) per
patients
n.a. Not cost-effective Academic
resources
Canada 77
With test no LY
gained
Schackman
2013 [29]
UGT1A1 Yes QALY $2,000,000* $100,000 Not cost-effective
unless assay
cost are low
Academic
resources
USA 83
*Authors assumed equal costs and efﬁcacy for different pharmaceuticals
BRAF, v-Raf murine sarcoma viral oncogene homolog B1; HLA, human leukocyte antigen; HSR, hyper sensitivity reaction; ICER, incremental cost-
effectiveness ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; LPA, lipoprotein-a; LYG, life-years-gained; LYS, life-years-saved; PGx,
pharmacogenetic; QALY, quality-adjusted-life-year; TPMT, thiopurine S-methyltransferase; UGT, UDP-glucuronosyltransferase.
doi:10.1371/journal.pone.0146262.t001
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Table 2. Outcomes and funding sources of pharmaco-economic PGx studies (of treatment comparisons involving PGx testing. Published between
August 2010 and September 2014. Note that numbers were rounded towards hundreds. Italic quantitative outcomes (ICERs) are not related to PGx scenario.
1st Author
(reference)
PGx test Analytical
validity
PGx test
reported
(y/n)
Outcom
Measure
Quantitative
outcome or
ICER (US$)
Cost-
effectiveness
threshold
($/QALY)
Conclusion
based on
outcome
Funding Country QHES
score
Olgiati 2012
[30]
5-HTTLPR No QALW Euro A $1,100 < 3 times the
GDP per
capita
Cost-effective
in high-
income
countries
Unknown Europe 61
Euro B $1,200
Euro C $1,200
Serretti 2011
[31]
5-HTTLPR No QALW $2,900 $50,000 Not cost-
effective
Unknown Italy 87
Reed 2011
[32]
8–14 risk
alleles
No QALY $98,100 $100,000 Cost-effective National Cancer
Institute
USA 83
$103,200
Djalalov
2012 [33]
APOE ε4 yes QALY CAN$38,000
($32,700)
No number May be
economically
attractive
Academic
resources
Canada 90
Kazi 2014
[34]
CYP2C19 No QALY Extendedly
dominated
$50,000 may improve
cost
effectiveness
American Heart
Association and
academic
resources
USA 90
$52,600
$35,800
$30,200
Reese 2012
[35]
CYP2C19 No CVE
avoided
Cost saving No number Dominant Unknown USA 64
Cost saving
$2,300
Cost saving
Sorich 2013
[36]
CYP2C19 No QALY AUS$6,300
($5,200)
AUS$30,00–
50,000
($24,500–
40,800)
Cost-effective Heart Foundation
of Australia
Australia 75
AUS$22,800
($18,600)
Crespin
2011 [37]
CYP2C19 *2 Yes QALY $10,100 $50,000 Cost-effective Academic
resources
USA 93
Lala 2013
[38]
CYP2C19 *2 Yes QALY Dominant n.a. Dominant Academic
resources
USA 83
Dominant
Panattoni
2012 [39]
CYP2C19 *2 No QALY NZ$ 24,600
($19,200)
NZ$50,000
($39,000)
Cost-effective Academic
resources
New
Zealand
75
Dominant
Pink 2013
[40]
CYP2C9 and
VKORC1
No QALY £13,200
($20,600)
£20,000–
30,000
($31,200–
46,700)
Cost-effective Academic
resources
UK 93
You 2012
[41]
CYP2C9 and
VKORC1
No QALY Dominated by
genotype–
guided
approach
$50,000 Dabigatran
150 mg
seems to be
cost-effective
No funding USA 84
$13,800 per
QALY
Dominated by
dabigatran 150
mg
You 2014
[42]
CYP2C9 and
VKORC1
No QALY $2,800 per
QALY
$50,000 Cost-effective Research Grants
Council of the
Hong Kong
special
administrative
Region, China
USA 70
(Continued)
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Table 2. (Continued)
1st Author
(reference)
PGx test Analytical
validity
PGx test
reported
(y/n)
Outcom
Measure
Quantitative
outcome or
ICER (US$)
Cost-
effectiveness
threshold
($/QALY)
Conclusion
based on
outcome
Funding Country QHES
score
de Lima
Lopes 2012
[43]
EGFR No QALY Dominant n.a. Dominant AstraZeneca Pte
Ltd.
Singapore 87
Handorf
2012 [44]
EGFR No QALY $110,600 $100,000 Cost-effective OSI
Pharmaceuticals/
Genentech
USA 90
Zhu 2013
[45]
EGFR No QALY and
LYG
$57,000 per
QALY
< 3 times the
GDP per
capita of
China
($16,300)
Not cost-
effective*
Shanghai Health
Bureau
China 90
$35,300 per
LYG
Kauf 2010
[46]
HLA-B
*5701
No HSR
avoided
$300 (60 days’
time horizon)
no number. Cost-effective Glaxo Smith
Kline, Inc.
USA 87
Rattanavipa-
pong 2013
[47]
HLA-B*1502 Yes QALY Epilepsy
patients
THB120,000
($3,634)
PGx test is
cost-effective
for
neuropathic
pain but not
for epilepsy
Academic
resources
Thailand 70
THB220,000
($6,700)
THB32,522,000
($984,800)
Neuropathic
pain patients
THB130,000
($3,900)-
THB35,877,00
($108,600)
Liu 2012 [48] IL-28B No QALY $50,400 No number Not clear Academic and
governmental
USA 83
Greeley
2011 [49]
KCNJ11 and
ABCC8
Yes QALY Dominant n.a. Dominant Academic
resources
USA 56
Parthan
2013 [50]
KIF6 No QALY $45,000 $100,000 May be cost
effective
Celera
corporation
USA 83
Vijayara-
ghavan
2012 [51]
KRAS Yes LYS Cost saving No number Cost-saving
in both US
and Germany
Roche Molecular
Systems, Inc.
USA and
Germany
75
Cost saving
$35,500 per
LYS
Hagaman
2010 [53]
TPMT No QALY $29,700 $50,000 Cost-effective Unknown USA 64
Thompson.
2014 [52]
TPMT No QALY Negative ICER n.a. Cost-saving
but also
health loss
Department of
Health UK
UK 88
Pichereau
2010 [54]
UGT1A1
*28
No neutropenia
avoided
€900–1,100
($1100–1300)
No number Cost-effective No speciﬁc
ﬁnancial support
for this study
France 84
ABCC, ATP-binding cassette transporter sub family C; APOE, apolipoprotein-E; CYP, cytochrome P-450; EGFR, epidermal growth factor receptor; GPD:
gross domestic product; HLA, human leukocyte antigen; HTTLPR, serotonin-transporter-linked polymorphic region; ICER, incremental cost-effectiveness
ratio; KCNJ, Potassium inwardly-rectifying channel, subfamily J; KRAS, Kirsten rat sarcoma viral oncogene homolog; LYG, life-years-gained; LYS, life-
years-saved; PGx, pharmacogenetic; QALW, quality-adjusted-life-week; QALY, quality-adjusted-life-year; THB, Thai Baht; TPMT, thiopurine S-
methyltransferase; UGT, UDP-glucuronosyltransferase; UK, United Kingdom; VKORC, Vitamin K epoxide reductase complex
* With the geﬁtinib patient assistance program (sponsored therapy after ﬁrst six months) it might be a cost-effective treatment option.
doi:10.1371/journal.pone.0146262.t002
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Sensitivity analysis
Until 2008, only 5 out of the 31(16%) studies performed both a univariate and probabilistic
sensitivity analysis, whereas since 2008 this were 35 out of the 49 (71%) studies (Fig 2B). One
of the major uncertainty factors was the lack of robust clinical evidence for clinical utility of the
PGx test itself. Hence, almost all authors had to define assumptions which were sometimes
solely based on expert opinion. Other frequently mentioned uncertainty factors were the costs
of the PGx tests and their real-world utility and performance. As a consequence of the uncer-
tainty around the included genotyping costs, several studies included a costs range in their
analysis. For example, Schackman et al. (2013) demonstrated that at a test cost of US$107,
genetic testing was not cost-effective. However, at a price of US$10 per test, the PGx test was
cost-effective [29]. Although variance in genotyping costs was frequently found to have a
major impact on the ICER, 11 out of the 38 studies (30%) assessed in this update did not
include a range of genotype costs in their sensitivity analysis (S1 Table). With respect to drug
costs, some studies showed that drug driven costs did not influence the study’s outcome. For
example, Crespin et al. (2011) showed in their sensitivity analysis that even if the costs of the
drugs guided by PGx testing dropped substantially, the non-PGx-test-guided drug remained
cost-effective [37].
Genes investigated and analytical validity of PGx test
In the period from 2000 until 2014, the majority of studies investigated the TPMT gene (17
studies). Among the studies presented in this update (i.e. from August 2010 onwards), most
investigations concerned the CYP2C19 screening tests (Fig 3A). We noticed that the CYP2C19
gene was studied in many different scenarios. Some studies assessed if the use of a CYP2C19
independent drug like prasugrel or ticagrelor would be a cost-effective treatment option
[35,36,38]. Similar results were found for CYP2C9 and VKORC1 testing in combination with
warfarin treatment, which was compared with CYP2C9 and VKORC1 independent novel oral
anticoagulants, like dabigatran.[41].
In general the analytical validity of PGx tests is high (>95%), nevertheless variation in the
analytical validity will in combination with the prevalence of a certain genetic trait determine
the predictive value of a test [97]. This can be of influence on the cost-effectiveness and was
nicely demonstrated by Kauf et al., who identified the negative predictive value as an important
input parameter for the costs-effectiveness of HLA-B5701 genotyping in their sensitivity anal-
ysis [46]. Nevertheless, underlying assumptions about the analytical validity of the test were
not reported. It was found that only 11 out of the 38 (30%) studies included since 2010, did
report underlying analytical validity of the PGx test (Table 1).
Outcome of the studies
There were 21 out of 80 (26%) studies which concluded that PGx testing was dominant (i.e.
resulting in clinical benefits as well as cost-savings). From 2010 onwards, most authors con-
cluded that PGx testing was cost-effective, while only four studies concluded that it was not
cost-effective (Fig 3B). In the period from 2010 until 2014, several studies provided the specific
conditions at which genetic testing might become cost-effective (Tables 1and 2). For example,
Dong et al. (2012) and Rattanavipapong et al. (2013) showed that the PGx tests could be cost-
effective depending on either the patient population or the disease [23,47]. Due to an imperfect
capability of PGx tests to differentiate between carriers of a genetic variant, some patients
might be misclassified and receive suboptimal treatment. As a result, two studies assessing
KRAS and BRAF testing and one study assessing TMPT testing found the PGx testing strategy
was cost-saving, but with a small health loss compared to the non-testing strategy [25,26,52].
Economic Evaluations of Genetic Testing
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Time horizon and discounting
To capture all costs, savings and effects of an intervention, a lifelong time horizon often seems
the best time horizon, although in some scenarios it may be argued that a shorter period is
acceptable. Before 2008, 12 out of 26 studies (46%) applied a time horizon of 12 months, and
only five (19%) studies applied a lifelong time window. Among the studies published since
2010, there was a broad range in the applied time horizons, from two weeks until lifetime (S1
Table). In addition, out of the 38 studies 17 (45%) applied a lifelong time horizon, six (16%)
Fig 3. Genes analysed (A) and study outcomes (B) of papers published between August 2010 and
September 2014.
doi:10.1371/journal.pone.0146262.g003
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studies applied a 30 year time horizon of which two studies also used a lifetime horizon. To
deal with uncertainty around the appropriated time horizon, different time horizons can be
used. We found that six out of 38 studies (16%) varied their time horizons [18,20,26,38,46,49].
In this way, insight into short- and long-term outcomes was given.
Discounting was applied for almost all studies published after 2006 that applied a time hori-
zon longer than one year. The majority of the studies used discounting at 3% annually for costs
and effects similarly (S1 Table).
Discussion of limitations
The limitations and uncertainties of an economic analysis have to be acknowledged in order to
judge the study on its merits. Nearly all of the newly included papers (i.e. published between
August 2010 and October 2014) discussed their limitations, uncertainties and possible short-
comings of their economic analysis (S2 Table). The topic most commonly discussed was the
lack of solid clinical evidence. As a result, many studies had to make assumptions or relied on
experts’ opinions. However, as mentioned before, most authors did include different efficacy
scenarios in their sensitivity analysis. Not all papers gave clear information about assumptions
concerning sensitivity and specificity of the PGx tests, and only three out of 38 (8%) mentioned
these assumptions as a limitation [45,49,51]. Another typical limitation for the effects of PGx
tests is the time in which test results will become available for clinical decision making. In cur-
rent analyses, test results were often assumed to be immediately available. However, this might
be an unrealistic assumption and only one out of 38 studies explicitly mentioned this assump-
tion as a limitation [23]. More general limitations were the lack of data with respect to hetero-
geneity in patient populations, hampering extrapolation of results to patients of different
ethnicities, subpopulations and/or country specific populations. Moreover, several papers men-
tioned the difficulties in extrapolating long-term clinical utility results from the short-term
clinical trials and lab studies.
Role of funding
Out of the 78 selected studies, 11 (14%) were funded by pharmaceutical companies. Before
2008, none of the studies was (directly) funded by pharmaceutical companies. In 2008 and
2009 only two (12.5%) out of 16 studies published in that period were funded by a pharmaceu-
tical company [70,71]. Between August 2010 and September 2014, 9 (24%) out of the 38
selected studies were funded by pharmaceutical companies (Tables 1 and 2). Regarding out-
comes and conclusions all of these studies concluded that PGx tests were dominant, cost-sav-
ing, or cost-effective. Among the remaining studies which were funded by other resources, 14%
concluded PGx tests were not cost-effective.
Quality assessment
The studies included through this update received a quality score according to the QHES.
There was 2% disagreement between the reviewers for which consensus was reached through
discussion. The average quality score was 76. The score which was given to each study is shown
in Tables 1 and 2. The majority of the studies (71%) were of high quality. On average, studies
concerning testing for EGFR received the highest rating and studies about the 21-gene assay
received the lowest rating. Some items were scored negative for the majority of the studies. One
of them was the item concerning the perspective of the analysis (i.e. societal, health care payers,
etcetera). Most studies did not explain why the perspective of the analysis was chosen. In addi-
tion, low scoring was received for separate reporting of the short-and long-term outcomes.
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Most studies did not make such a distinction. Lastly, the direction and magnitude of potential
biases were often not discussed.
Discussion
Principal findings
Since 2004, there is an increase in the number of studies evaluating the economic value of PGx
tests and this increase accelerated from 2008 onwards. There were not that many economic
evaluations of PGx tests available as one might expect given the unravelling of the whole
human genome in 2003, the clinical possibilities, and the fast development and decreasing
costs of genetic tests [98]. This could be related to limited implementation of pharmacogenetic
knowledge into daily clinical practice [5]. Reasons for this are the uncertainty about clinical rel-
evance, concerns about the availability of genetic data and considerable differences in cost-
effectiveness which are found, in particular between countries [5,99,100].
Many studies included through this update did not assess the intrinsic value of the PGx test
itself, but compared a PGx test treatment combination with an alternative treatment. For
example, the tests for CYP2C19 or, both CYP2C9 and VKORC1 were incorporated in several
models as the current treatment option in combination with clopidogrel or warfarin treatment,
respectively. The alternative treatment options, which were assessed in the included studies,
were independent of pharmacogenetics and were found to be cost-effective. Therefore, in cost-
effectiveness analysis of antithrombotic therapy, there seems an ongoing movement away from
pharmacogenetic testing, towards treatment options with compounds that are, so far, consid-
ered to be independent of pharmacogenetics.
Before 2008, most analyses were cost-effectiveness analyses, however since 2008 there has
been a trend towards the use of cost-utility analyses. Cost-utility analysis is currently consid-
ered as the preferred type of analysis for health care choices as is advised in several national
guidelines, although other types can be suitable depending on the specific study ([1,102].
Before 2008, most studies performed only a simple univariate sensitivity analysis, if any [9].
We found that more recent studies performed both univariate and probabilistic sensitivity
analyses. This combination is also advised in several national guidelines for pharmacoeco-
nomic evaluation and is a part of the QHES checklist [16,101,102]. As a result of these more
comprehensive sensitivity analyses, the quality of economic evaluations appears to be
improved over the last decade. However, we found that differences in genotyping costs were
not always included in the sensitivity analysis which leaves room for improvement.
Among the new studies included in this update (i.e. since 2010), considerable differences in
the length of the time horizon were noticed, varying from two weeks to lifelong. A time horizon
shorter than a year was primarily related to the expected relevant clinical outcomes. Interest-
ingly, there were differences in the time horizon between studies investigating the same genes.
For example, Kazi et al. and Panattoni et al. applied a lifelong time horizon [34,39], whereas
others applied a time horizon of 15 months [35,38]. All studies discussed at least some limita-
tions and a lack of robust clinical evidence was most frequently mentioned as an important
limitation contributing to uncertainty in the analysis. Although studies frequently made
assumptions about analytical validity of PGx tests as well as about the rapid clinical availability,
these were often not discussed as limitations or studied in sensitivity or scenario analyses.
Besides the analytical validity, the clinical validity of PGx tests is important. In general this is
the same as an effect estimate of a PGx test. As such, the clinical validity is correctly embedded
in an economic evaluation. However, this does not apply for all PGx tests, because some PGx
tests involve an analysis of multiple genetic variations. These variations can all contribute to a
similar genotype prediction and therefore the clinical validity depends on the number and type
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of variant alleles analysed. For example, CYP2C19 genotyping which depends on general
molecular genetic analysis of single nuclear polymorphisms to detect variant alleles. Several
studies included in this review studied only the CYP2C192 allele [37–39]. However, other
allele like the 3 allele can also effect CYP2C19 activity and give a similar clinical effect as the 2
allele [103]. When more variant alleles are analysed the clinical validity of the PGx test will
increase, although some variants are rare and will contribute little. With the ongoing and rapid
increase of knowledge about variant alleles, it is important economic evaluations report the
variant alleles on which their assumptions about effects of genotyping (i.e. clinical validity)
were based. For the example of CYP2C19, two out of the six studies involving the CYP2C19
gene, did not specify which alleles were included [34,36]. This hampers the extrapolation of
their findings towards populations of a different ethnicity and other laboratories.
Compared to studies published before 2008, studies were more commonly funded by phar-
maceutical companies. Interestingly, all of these sponsored studies concluded that PGx tests
were dominant, cost-saving, or cost-effective whereas the few studies which concluded other-
wise were financed by academic, governmental, or unknown resources. It is known that studies
funded by pharmaceutical companies publish more positive results when compared to studies
funded by other resources which is in line with our results [104]. These positive biased results
are not related towards the quality of the studies, but to the comparison which is made or pub-
lication bias [105]. For many of the economic evaluations in this review, assumptions about the
effect of the genetic test were made. Furthermore, analytical validity was often not included in
the model. This leaves room to bias result in favour of a preferred treatment strategy. There-
fore, attention should be given toward assumptions about these aspects, especially when studies
are funded by pharmaceutical companies or if the funding is not reported.
Most studies included in this review concluded that the application of PGx tests was cost-
effective. Yet, the conclusions were not unambiguous, often due to the uncertainties in the eco-
nomic models. Another reason for this was that most of the newly included studies did not
assess the intrinsic value of the PGx test itself, but a scenario involving one or more PGx tests.
Although such estimates are important for the economic impact of the application of personal-
ized medicine, they do not provide information about the cost-effectiveness of the PGx test
itself and therefore outcomes can be different. To improve generalizability between studies, an
additional scenario analysis in which equal costs and efficacy of the compared treatment strate-
gies are assumed, to assess the intrinsic value of the PGx tests, could be used. Such an approach
would especially be interesting when the comparator drug is under patent and drug costs are
likely to decrease in the future. Another aspect creating different conclusions was the genetic
variety between study populations. This was clearly described by some papers which men-
tioned the specific conditions like a specific geographic region or a disease for which the genetic
testing was cost-effective. For example, PGx testing for HLA-B5702 was cost-effective in Sin-
gaporean Chinese and Malays, but not in Singaporean Indians [23]. In addition, Rattanavipa-
pong et al. (2013) found that HLA-B5702 testing was cost-effective in epileptic patients, but
not in neuropathic pain patients [47].
Comparison with previous literature reviews
For the new studies included in this update (i.e. since 2010), an average QHES-quality score of
76 was found. This was is in line with the results from the review fromWong et al. about phar-
macoeconomics of PGx tests. They found an average quality score of 77 [13]. However, it was
lower compared to a related review of Djalalov et al., who found an average quality score of 90
[10]. This is likely due to the subjective nature of some items in the quality assessment. For
example, ‘item 3’ asks if the used estimates for the analysis were from the best available source,
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and is therefore quite sensitive to the interpretation of the reviewer [16]. Previous review stud-
ies pointed out that the methodology of economic evaluations of PGx tests is often heteroge-
neous and of insufficient quality [9,11]. Assasi et al. found that economic PGx studies which
were of low quality (i.e. QHES score of< 50), frequently failed to handle uncertainty, did not
inform about the study’s limitations, and did not discuss direction and magnitude of potential
uncertainty [11]. Among the studies included in this update (i.e. since 2010), most of the
authors discussed uncertainties and except for the study by Tiamkao et al., all incorporated
uncertainty in a sensitivity analysis [24]. However, direction and magnitude of potential bias
was still not sufficiently discussed and remains a major point for improvement.
Limitations of our approach
This review has some limitations. Firstly, we did not include studies from other databases than
PubMed or grey literature and we only included English written studies. Therefore some stud-
ies might have been missed. In general, studies that are not indexed in MEDLINE or written in
English do not have a large impact on reviews’ outcomes [106]. Nevertheless, these studies are
frequently of lower quality, and therefore the average quality of the studies included in our
review might have been slightly overestimated. However, based on the comparison with other
reviews we found a slightly lower average quality score. Lastly, publication bias can always
influence the findings of a review. Therefore cost-effectiveness of PGx tests could be
overestimated.
Recommendations
Based on the quality assessment, reporting of the reasons behind the chosen perspective and
the type of economic model can improve the quality of economic evaluations of PGx tests. In
addition, reporting of both short-and long-term outcomes and the influence of potential bias,
in terms of direction and magnitude on the cost-effectiveness estimates could be improved.
Although a substantial and persistent increase in the use of both univariate and probabilistic
sensitivity analyses was observed since 2008, there is still room for improvement by using a
combination of these techniques instead of one technique, among several studies published
since 2008. Publication bias or biased comparators might favour cost-effectiveness of PGx
tests. Among studies funded by companies with conflicting interests, the risk on this kind of
bias should be critically assessed. In our previous reviews the main limitation that was identi-
fied was the unavailability of clinical evidence [1,9]. Although this remains an important issue,
based on our new findings we can add some recommendations which are more applicable to
implementation of PGx tests in clinical practice. First, the clinical validity of a test, i.e. the capa-
bility of the test to predict phenotypes with a clinical effect and the analytical validity should be
reported as is recommended by the US Academy of Managed Care Pharmacy [107]. Both
parameters should be included in a sensitivity analysis. In addition, the variant alleles on which
these parameters were based should be reported. For some PGx tests, these estimates might be
unknown. In this case, a better approach towards this problem would be inclusion of an uni-
variate sensitivity analysis with different cut-off values for the analytical and clinical validity of
the PGx test. In this way, a minimum for the analytical and clinical validity can be generated.
Note that with an increase in analysed alleles and as such the clinical validity, the price for the
PGx test usually increases as well. Secondly, different turnaround times in which PGx test
results would become available for healthcare professionals after requesting the test would be
very informative. If direct availability of the genetic test is assumed, for example in the case of
pre-emptive genotyping, this should be clearly stated in the method section. This way, the gen-
eralizability of results to other countries where PGx tests are available would improve. In
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addition, a range of costs for the genetic test should be evaluated in univariate and if applicable
probabilistic sensitivity analyses. Furthermore, we recommend the addition of a scenario analy-
sis in which drug costs between comparator groups are equalized to give information about the
intrinsic value of the PGx test itself.
Conclusion
Application of PGx tests was mostly found to be a cost-effective or cost-saving strategy,
although some studies concluded otherwise which underlines the importance of future studies
assessing the cost-effectiveness of PGx tests. We found that only the minority of recent phar-
macoeconomic evaluations assessed the intrinsic value of the PGx tests. New compounds that
are not affected by genetics, are emerging as cost-effective alternatives for pharmacogenetic
testing strategies. Over the last decade, there was an increase in the number of studies and in
the reporting of quality associated characteristics. Due to rapid development in analytical tech-
niques, reporting of analytical and clinical validity of the assessed PGx test is recommended for
future evaluations. Furthermore robust clinical evidence regarding PGx tests’ efficacy is
warranted.
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